Loss of heterozygosity at BRCA1-2 loci in hereditary and sporadic ovarian cancers

• Autorzy: Brozek I , Ochman K , Debniak J , Morzuch L , Ratajska M , Stepnowska M , Stukan M , Emerich J , Limon J
• Języki publikacji: EN

Abstrakty

EN

Loss of heterozygosity at BRCA 1/2 loci in breast and ovarian tumors is a suggested risk factor for germline BRCA1/2 mutation status. We evaluated the presence of losses of selected microsatellite markers localized on chromosomes 17 and 13q in hereditary and sporadic ovarian tumors. 151 consecutive primary ovarian tumors (including 21 with BRCA1/2 mutations and 130 without the mutations) were screened for loss of heterozygosity at loci on chromosomes 17 and 13q. Losses of heterozygosity of at least one microsatellite marker localized on chromosomes 17 and 13q were revealed in 123 (81.5%) and 104 (68.9%) tumors, respectively. Losses of all informative markers on chromosomes 17 and 13 occurred in 30 (19.9%) and 31 (20.5%) tumors, respectively. There was no difference in the frequency of losses at BRCA1 intragenic markers (D17S855 and D17S1323) between BRACA1-positive and BRCA1-negative patients. The frequency of losses on chromosome 17 was higher in high-grade than in low-grade carcinomas. Loss of heterozygosity on chromosomes 17 and 13q is a frequent phenomenon in both hereditary and sporadic ovarian cancers. The frequency of losses at BRCAl intragenic markers in the ovarian tumor tissue is not strongly related to the presence of BRCAl germline mutations.

Słowa kluczowe

EN

loss; heterozygosity; BRCA1-2 mutation status; hereditary disease; sporadic cancer; ovarian cancer; mutation

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 2009
• Tom: 50
• Numer: 4
• Opis fizyczny: p.379-384,fig.,ref.

Twórcy

autor

Brozek I

• Department of Bioloy and Genetics, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland
• Regional Oncological Center of Gdańsk, Poland

autor

Ochman K

• Department of Bioloy and Genetics, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland

autor

Debniak J

• Department of Gynecology, Medical University of Gdańsk, Poland

autor

Morzuch L

• Department of Bioloy and Genetics, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland

autor

Ratajska M

• Department of Bioloy and Genetics, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland

autor

Stepnowska M

• Department of Bioloy and Genetics, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland

autor

Stukan M

• Department of Gynecology, Medical University of Gdańsk, Poland

autor

Emerich J

• Department of Gynecology, Medical University of Gdańsk, Poland

autor

Limon J

• Department of Bioloy and Genetics, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland
• Regional Oncological Center of Gdańsk, Poland

Bibliografia

• Berchuck A, Heron K, Carney ME, Lancaster JM, Fraser EG, Vinson V, et al. 1998. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4: 2433-2437.
• Brożek I, Ochman K, Dębniak J, Morzuch L, Ratajska M, Stępnowska M, et al. 2008. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 108: 433-437.
• Chisholm KM, Goff BA, Garcia R, King M-C, Swisher EM, 2008. Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers. Cancer Genet Cytogen 183: 41-48.
• Dion F, Mes-Masson A-M, Seymour RJ, Provencher D, Tonin PN, 2000. Allelotyping defines minimum imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 19: 1466-1472.
• Garcia A, Bussaglia E, Machin P, Matias-Guiu X Prat J, 2000. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation. Int J Gynecol Pathol 19: 152-157.
• Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE, 2002. Frequency of BRCAl dysfunction in ovarian cancer. J Nat Cancer Inst 94: 61-67.
• Górski B, Dębniak T, Jakubowska A, Cybulski C, Huzarski T, Byrski T, et al. 2003. Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers. J Appl Genet 44: 419-423.
• Gras E, Cortes J, Diez A, Alonso C, Matias-Guiu X, Baiget M, Prat J, 2001. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 92: 787-795.
• Jongsma APM, Piek JMJ, Zweemer RP, Verheijen RH, Klein Gebbinck J W, van Kamp GJ, et al. 2002. Molecular evidence for putative tumor suppressor genes on chromosome 13q specific to BRCAl related ovarian and fallopian tube cancer. J Clin Pathol 55: 305-309.
• Kashima K, Oite T, Aoki Y, Takakuwa K, Aida H, Nagata H, et al. 2000. Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancer. Jpn J Cancer Res 91: 399-409.
• Lee KR, Tavassoli FA, Prat J, Dietel M, 2003. Surface epithelial-stromal tumours. In: Tavassoli FA, Deville P, eds. WHO classification of tumours, pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press: 117-145.
• Menkiszak J, Gronwald J, Górski B, Jakubowska A, Huzarski T, Byrski T, et al. 2003. Hereditary ovarian cancer in Poland. Int J Cancer 106: 942-945.
• Otis CN, Krebs PA, Quezado MM, Albuquerque A, Bryant B, San Juan X, et al. 2000. Loss of heterozygosity in P53, BRCA1 and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior. Hum Pathol 31: 233-238.
• Piretti M, Powell DE, Gallion HH, Case EA, Conway PA and Turker MS, 1995. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian cancer. Human Pathol 26: 393-397.
• Piretti M and Turker MS, 1997. Mutation, ageing and ovarian cancer. Lancet 349: 700-701.
• Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. 2008. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17.
• Russell PA, Pharoah PD, De-Foy K, Ramus SJ, Symmonds I, Wilson A, et al. 2000. Frequent loss of BRCA1, mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 87: 317-321.
• Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, et al. 1995. Mutation analysis of BRCA1 gene in ovarian cancers. Cancer Res 55: 2998-3002.
• Wang C, Horiuchi A, and Imai T, 2004. Expression of BRCAI protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCAI gene. J Pathol 202: 215-223.